Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW
2022;34(9):12341247.e9
Its also worth noting that the three ingredients have only been studied individuallytheres no research on whether this specific combination works better, worse, or the same as each one on its own
ICYMI, GLP-1 has become a very buzzy word in weight management discourse over the past couple of years, so its worth giving a brief explanation of exactly what it is
In agreement with expectations, the first outcome trial of a GLP-1RA, the ELIXA trial of the short-acting lixisenatide, an exendin-4 derivative with properties almost identical to those of exendin-4 or exenatide (stable, full agonists of the GLP-1 receptor), showed no increased cardiovascular risk in a patient group with severely increased CVD risk
A typical titration might start at 0.5 mg per week, increase to 2 mg, and eventually reach doses of 8 mg or 12 mg depending on your providers recommendation